Biostax

Biostax EBIT Margin

The EBIT Margin (Operating Margin) of Biostax (BTAX) as of Nov 1, 2026 is -3,598.94 %. In the previous year, EBIT Margin (Operating Margin) was -407,768.57 % — a change of -99.12% (higher).

EBIT Margin

-3,598.94 %

YoY

-99.12%

Last updated:

EBIT Margin (Operating Margin) of Biostax is 2018 -3,598.94 % . EBIT Margin (Operating Margin) of Biostax was 2017 -407,768.57 % . It decreases by -99.12% higher compared to the previous year.

Biostax's operating (EBIT) margin stands at -3,598.9%, up from -65,287.0% several years earlier.

The Biostax EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2015
-65,287.04 USD
Jan 1, 2016
-407,768.57 USD
Jan 1, 2018
-3,598.94 USD
The Biostax EBIT Margin history
YEAREBIT MarginYoY
-3,598.94 %-99.12%
-407,768.57 %+524.58%
-65,287.04 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biostax Stock analysis

What does Biostax do? Immune Therapeutics, Inc. develops and markets pharmaceutical, biotechnology, and MedTech products through its subsidiary BiostaxRx, which focuses on treating inflammaging disease. The company's product portfolio includes Londonal, a once-a-day immune system regulator for HIV/AIDS management, and JKB-122, a therapy targeting Autoimmune Hepatitis, NAFLD, and NASH with anti-fibrotic and anti-inflammatory properties. Biostax has partnerships in autoimmunity and immune restoration fields to deliver solutions for patients with autoimmunity, chronic inflammation, infection, and cancer. BiostaxRx specifically addresses inflammaging disease within its treatment focus. Biostax Corp's revenue streams come from the sale of Londonal and JKB-122 to healthcare providers and patients seeking treatments for immune-related conditions. The company markets its products to medical professionals and institutions specializing in autoimmune disorders, chronic inflammation, and oncology. Its focus on specific therapeutic areas allows it to target healthcare segments requiring immune modulation and anti-inflammatory solutions. The company's partnerships support its delivery of specialized treatments for chronic conditions such as HIV/AIDS, liver diseases, and cancer-related inflammation. The company's product lines are designed for specific patient segments including those with HIV/AIDS, Autoimmune Hepatitis, NAFLD, NASH, and inflammaging. Londonal is positioned for HIV/AIDS management while JKB-122 targets liver conditions and inflammation. BiostaxRx's focus on inflammaging disease aligns with the growing market for age-related immune health solutions. The company's marketing strategy emphasizes specialized treatments for complex conditions where current therapies are limited or ineffective. Biostax is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biostax stock

EBIT Margin (Operating Margin) of Biostax is -3,598.94 % in 2018.

EBIT Margin (Operating Margin) of Biostax changed from -407,768.57 % to -3,598.94 %, representing a -99.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Biostax since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Biostax with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Biostax

All Key Metrics — Biostax